Q1 Earnings Forecast for biote Issued By B. Riley

biote Corp. (NASDAQ:BTMD) – Investment analysts at B. Riley issued their Q1 2025 earnings per share estimates for shares of biote in a research note issued to investors on Thursday, March 13th. B. Riley analyst J. Van. Sinderen anticipates that the company will earn $0.04 per share for the quarter. The consensus estimate for biote’s current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote’s Q2 2025 earnings at $0.05 EPS, FY2025 earnings at $0.29 EPS, FY2026 earnings at $0.42 EPS and FY2027 earnings at $0.71 EPS.

Separately, Craig Hallum lowered their price target on biote from $12.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, March 13th.

biote Trading Up 6.4 %

Shares of NASDAQ BTMD opened at $4.00 on Monday. biote has a 12-month low of $3.04 and a 12-month high of $8.44. The company has a market cap of $217.35 million, a P/E ratio of 15.38 and a beta of 1.07. The stock has a fifty day moving average price of $4.92 and a 200 day moving average price of $5.53.

Insider Activity at biote

In other biote news, major shareholder Guines Llc bought 750,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was bought at an average cost of $3.22 per share, for a total transaction of $2,415,000.00. Following the completion of the purchase, the insider now directly owns 3,820,938 shares of the company’s stock, valued at approximately $12,303,420.36. The trade was a 24.42 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 13.90% of the stock is owned by insiders.

Institutional Trading of biote

Several large investors have recently modified their holdings of the business. Wasatch Advisors LP grew its stake in shares of biote by 8.4% during the third quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company’s stock valued at $7,772,000 after acquiring an additional 107,792 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of biote by 0.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company’s stock valued at $4,211,000 after acquiring an additional 3,065 shares in the last quarter. State Street Corp grew its stake in shares of biote by 13.7% during the third quarter. State Street Corp now owns 475,491 shares of the company’s stock valued at $2,653,000 after acquiring an additional 57,290 shares in the last quarter. Kanen Wealth Management LLC bought a new position in shares of biote during the fourth quarter worth about $1,791,000. Finally, Northern Trust Corp grew its stake in biote by 9.9% in the fourth quarter. Northern Trust Corp now owns 288,336 shares of the company’s stock worth $1,782,000 after purchasing an additional 25,873 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.